Biotica Pharma

Biotica Pharma, also referred to as Biotica Pharmaceuticals, was a U.S.-based early-stage biopharmaceutical company focused on discovering and developing cannabinoid-based medicines. The company positioned its research around a proprietary BPRx platform built from combinations of phytocannabinoids and endocannabinoids. Publicly described lead programs included BPRx-060216 for eosinophilic esophagitis and BPRx-060234 for early Alzheimer's disease, with broader stated interests in pain, neurodegeneration, and oncology. Available sources indicate the company remained preclinical and did not advance into later-stage clinical development. Recent secondary-source profiles describe the company as inactive or deadpooled.